Abstract
The number of cost-of-illness (COI) studies has expanded considerably over time. One outcome of this growth is that the reported COI estimates are inconsistent across studies, thereby raising concerns over the validity of the estimates and methods. Several factors have been identified in the literature as reasons for the observed variation in COI estimates. To date, the variation in the methods used to calculate costs has not been examined in great detail even though the variations in methods are a major driver of variation in COI estimates. The objective of this review was to document the variation in the methodologies employed in COI studies and to highlight the benefits and limitations of these methods.
The review of COI studies was implemented following a four-step procedure: (i) a structured literature search of MEDLINE, JSTOR and EconLit; (ii) a review of abstracts using pre-defined inclusion and exclusion criteria; (iii) a full-text review using pre-defined inclusion and exclusion criteria; and (iv) classification of articles according to the methods used to calculate costs. This review identified four COI estimation methods (Sum_All Medical, Sum_Diagnosis Specific, Matched Control and Regression) that were used in categorising articles. Also, six components of direct medical costs and five components of indirect/non-medical costs were identified and used in categorising articles.
365 full-length articles were reflected in the current review following the structured literature search. The top five cost components were emergency room/inpatient hospital costs, outpatient physician costs, drug costs, productivity losses and laboratory costs. The dominant method, Sum_Diagnosis Specific, was a total costing approach that restricted the summation of medical expenditures to those related to a diagnosis of the disease of interest.
There was considerable variation in the methods used within disease subcategories. In several disease subcategories (e.g. asthma, dementia, diabetes mellitus), all four estimation methods were represented, and in other cases (e.g. HIV/AIDS, obesity, stroke, urinary incontinence, schizophrenia), three of the four estimation methods were represented. There was also evidence to suggest that the strengths and weaknesses of each method were considered when applying a method to a specific illness. Comparisons and assessments of COI estimates should consider the method used to estimate costs both as an important source of variation in the reported COI estimates and as a marker of the reliability of the COI estimate.
Similar content being viewed by others
References
Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001; 19 (2): 207–213
Shaya FT, Mullins CD, Wong W. Incidence versus prevalence modeling in pharmacoeconomics. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2 (5): 435–442
Mittendorf T, Merkesdal S, Huelsemann JL, et al. Implementing standardized cost categories within economic evaluations in musculoskeletal diseases. Eur J Health Econ 2003; 4 (1): 43–49
Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–462
Rice DP. Estimating the costs of illness. Health Economics Series No. 6. DHEW Publication No. (PHS)947-6. Rockville (MD): U.S. Department of Health, Education and Welfare, 1966
Cooper BS, Rice DP. The economic costs of illness revisited. Soc Secur Bull 1976; 39 (2): 21–36
Berk A, Paringer L, Mushkin SJ. The economic costs of illness: fiscal 1975. Med Care 1978; 26 (9): 785–790
Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy 1987; 8: 317–323
DeLeire T, Manning W. Labor market costs of illness: prevalence matters. Health Econ 2004; 13 (3): 239–250
Pauly MV, Nicholson S, Xu J, et al. A general model of the impact of absenteeism on employers and employees. Health Econ 2002; 11 (3): 221–231
Koopmanschap MA. Cost-of-illness studies: useful for health policy? Pharmacoeconomics 1998; 14 (2): 143–148
Mooney G, Wiseman V. Burden of disease and priority setting [comment]. Health Econ 2000; 9 (5): 369–372
Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992; 2 (1): 1–4
Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000; 320 (7245): 1335
Kaste M, Fogelholm R, Rissanen A. Economic burden of stroke and the evaluation of new therapies. Public Health 1998; 112 (2): 103–112
Xuan J, Duong PT, Russo PA, et al. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000; 6: 693–7000
Norlund A, Apelqvist J, Bitzen PO, et al. Cost of illness of adult diabetes mellitus underestimated if comorbidity is not considered. J Intern Med 2001; 250 (1): 57–65
Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health 2001; 4 (4): 329–334
Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998; 39 (7): 776–786
Andersen CK, Andersen K, Kragh-Sorensen P. Cost function estimation: the choice of a model to apply to dementia. Health Econ 2000; 9 (5): 397–409
Leon J, Neumann PJ. The cost of Alzheimer’s disease in managed care: a cross-sectional study. Am J Manag Care 1999; 5 (7): 867–877
Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff 2001; 20 (6): 233–241
Hodgson TA. Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell, et al. (Health Policy, 8 (1987) 317-323). Health Policy 1989; 11 (1): 57–60
Cummings JL, Frank JC, Cherry D, et al. Guidelines for managing Alzheimer’s disease: part I. Assessment. Am Fam Physician 2002; 65 (11): 2263–2272
Pradalier A, Auray JP, El Hasnaoui A, et al. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study. Pharmacoeconomics 2004; 22 (15): 985–999
Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53 (10): 1471–1478
Wlodarczyk J, Whyte P, Cockrum P, et al. Pterygium in Australia: a cost of illness study. Clin Exp Ophthalmol 2001; 29 (6): 370–375
Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004; 22 (17): 3524–3530
Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004; 15 (3): 526–536
Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med 2004; 5 (2): 93–98
Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004; 63 (4): 395–401
Halpern MT, Schmier JK, Richner R, et al. Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidity. J Asthma 2004; 41 (1): 117–126
Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184: 346–351
van den Brandhof WE, De Wit GA, de Wit MA, et al. Costs of gastroenteritis in The Netherlands. Epidemiol Infect 2004; 132 (2): 211–221
Penson DF, Moul JW, Evans CP, et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004; 171 (6 Pt 1): 2250–2254
Nsengiyumva G, Druet-Cabanac M, Nzisabira L, et al. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. Epilepsia 2004; 45 (6): 673–677
Turner DA, Shaw C, McGrother CW, et al. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004; 93 (9): 1246–1252
Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004; 91 (1): 77–83
Yelin E, Cisternas MG, Pasta DJ, et al. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum 2004; 50 (7): 2317–2326
Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164 (15): 1653–1661
Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20 (7): 455–462
Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer’s disease: the role of comorbid conditions, disease stage, and pharmacotherapy. Fam Med 2002; 34 (7): 528–535
Dawson KG, Gomes D, Gerstein H, et al. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002; 25 (8): 1303–1307
Carr VJ, Neil AL, Halpin SA, et al. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003; 37 (1): 31–40
Carapetis JR, Russell DM, Curtis N. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine 2004; 23 (6): 755–761
Pirson M, Dramaix M, Struelens M, et al. Costs associated with hospital-acquired bacteraemia in a Belgian hospital. J Hosp Infect 2005; 59 (1): 33–40
Calhoun EA, McNaughton Collins M, Pontari MA, et al. The economic impact of chronic prostatitis. Arch Intern Med 2004; 164 (11): 1231–1236
Stothers L, Thom D, Calhoun E. Urologic diseases in America project: urinary incontinence in males: demographics and economic burden. J Urol 2005; 173 (4): 1302–1308
Penberthy LT, Towne A, Garnett LK, et al. Estimating the economic burden of status epilepticus to the health care system. Seizure 2005; 14 (1): 46–51
Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004; 20 (12): 1929–1936
Verstappen SM, Verkleij H, Bijlsma JW, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004; 63 (7): 817–824
Coello R, Charlett A, Wilson J, et al. Adverse impact of surgical site infections in English hospitals. J Hosp Infect 2005; 60 (2): 93–103
Lanzieri TM, Parise MS, Siqueira MM, et al. Incidence, clinical features and estimated costs of congenital rubella syndrome after a large rubella outbreak in Recife, Brazil, 1999–2000. Pediatr Infect Dis J 2004; 23 (12): 1116–1122
Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64 (3): 396–402
Oliva J, Lobo F, Molina B, et al. Direct health care costs of diabetic patients in Spain. Diabetes Care 2004; 27 (11): 2616–2621
Wyss K, Hutton G, N’Diekhor Y. Costs attributable to AIDS at household level in Chad. AIDS Care 2004; 16 (7): 808–816
Zohrabian A, Meltzer MI, Ratard R, et al. West Nile virus economic impact, Louisiana, 2002. Emerg Infect Dis 2004; 10 (10): 1736–1744
Hallert E, Husberg M, Jonsson D, et al. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology 2004; 43 (11): 1374–1382
Gil A, Carrasco P, Jimenez R, et al. Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999–2000. Vaccine 2004; 22 (17–18): 2221–2225
Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30 (6): 1318–1325
O’Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003; 25 (3): 1017–1038
Gendo K, Sullivan SD, Lozano P, et al. Resource costs for asthma-related care among pediatric patients in managed care. Ann Allergy Asthma Immunol 2003; 91 (3): 251–257
Leigh JP, Yasmeen S, Miller TR. Medical costs of fourteen occupational illnesses in the United States in 1999. Scand J Work Environ Health 2003; 29 (4): 304–313
Snowden CB, Miller TR, Jensen AF, et al. Costs of medically treated craniofacial conditions. Public Health Rep 2003; 118 (1): 10–17
Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S23–S31
Halpern MT, Musin A, Sondhi S. Economic analysis of the Confronting COPD survey: methodology. Respir Med 2003; 97 Suppl. C: S15–S22
Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97 Suppl. C: S3–S14
Piperno D, Huchon G, Pribil C, et al. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S33–S42
Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S51–S59
Britton M. The burden of COPD in the UK: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S71–S79
Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S81–S89
Ekman M, Johnell O, Lidgren L. The economic cost of low back pain in Sweden in 2001. Acta Orthop 2005; 76 (2): 275–284
Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 2004; 27 (11): 1034–1039
Soderlin MK, Kautiainen H, Skogh T, et al. Quality of life and economic burden of illness in very early arthritis: a population based study in southern Sweden. J Rheumatol 2004; 31 (9): 1717–1722
O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003; 3 (1): 7
O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3 (1): 17
Birnbaum HG, Leong SA, Oster EF, et al. Cost of stress urinary incontinence: a claims data analysis. Pharmacoeconomics 2004; 22 (2): 95–105
Garis RI, Farmer KC. Examining costs of chronic conditions in a Medicaid population. Manag Care 2002; 11 (8): 43–50
Verboom P, Hakkaart-Van L, Sturkenboom M, et al. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002; 147 (4): 716–724
Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46 (3): 361–370
Hemmila HM. Quality of life and cost of care of back pain patients in Finnish general practice. Spine 2002; 27 (6): 647–653
Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med 2004; 46 (4): 398–412
Andersen CK, Lauridsen J, Andersen K, et al. Cost of dementia: impact of disease progression estimated in longitudinal data. Scand J Public Health 2003; 31 (2): 119–125
Tu F, Anan M, Kiyohara Y, et al. Analysis of hospital charges for ischemic stroke in Fukuoka, Japan. Health Policy 2003; 66 (3): 239–246
Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/ hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003; 42 (12): 1415–1423
Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23 (5): 723–729
Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64 (12): 1465–1475
Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 2004; 83 (1): 25–32
Martin BC, Ganguly R, Pannicker S, et al. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin 2003; 19 (8): 771–780
Guillemin F, Durieux S, Daures JP, et al. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 2004; 31 (7): 1297–1304
Dewey HM, Thrift AG, Mihalopoulos C, et al. Lifetime cost of stroke subtypes in Australia: findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003; 34 (10): 2502–2507
Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7527 patients. Arthritis Rheum 2003; 48 (10): 2750–2762
Murman DL, Kuo SB, Powell MC, et al. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 2003; 61 (7): 944–949
Herjavecz I, Nagy GB, Gyurkovits K, et al. Cost, morbidity, and control of asthma in Hungary: the Hunair Study. J Asthma 2003; 40 (6): 673–681
Sansom SL, Cotter SM, Smith F, et al. Costs of a hepatitis A outbreak affecting homosexual men: Franklin County, Ohio, 1999. Am J Prev Med 2003; 25 (4): 343–346
Norlund A, Alvegard T, Lithman T, et al. Prostate cancer: prevalence-based healthcare costs. Scand J Urol Nephrol 2003; 37 (5): 371–375
Burge RT, King AB, Balda E, et al. Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025. Value Health 2003; 6 (5): 574–583
Soderlin MK, Kautiainen H, Jonsson D, et al. The costs of early inflammatory joint disease: a population-based study in southern Sweden. Scand J Rheumatol 2003; 32 (4): 216–224
Boonen A, van der Heijde D, Landewe R, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62 (8): 732–740
Boonen A, van der Heijde D, Landewe R, et al. Costs of ankylosing spondylitis in three European countries: the patient’s perspective. Ann Rheum Dis 2003; 62 (8): 741–747
Stewart S, Murphy N, Walker A, et al. The current cost of angina pectoris to the National Health Service in the UK. Heart 2003; 89 (8): 848–853
Melton III LJ, Gabriel SE, Crowson CS, et al. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003; 14 (5): 383–388
Finnern HW, Sykes DP. The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int 2003; 14 (5): 429–436
Rothbard AB, Metraux S, Blank MB. Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS. Psychiatr Serv 2003; 54 (9): 1240–1246
Jarbrink K, Fombonne E, Knapp M. Measuring the parental, service and cost impacts of children with autistic spectrum disorder: a pilot study. J Autism Dev Disord 2003; 33 (4): 395–402
Rigaud AS, Fagnani F, Bayle C, et al. Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol 2003; 16 (3): 140–145
Burd L, Klug MG, Coumbe MJ, et al. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol 2003; 18 (8): 555–561
Braud AC, Levy-Piedbois C, Piedbois P, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 2003; 21 (9): 671–679
Birnbaum H, Morley M, Leong S, et al. Lower respiratory tract infections: impact on the workplace [published erratum appears in Pharmacoeconomics 2003; 21 (12): 883]. Pharmacoeconomics 2003; 21 (10): 749–759
Youman P, Wilson K, Harraf F, et al. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; 21 Suppl. 1: 43–50
Leader S, Yang H, De Vincenzo J, et al. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health 2003; 6 (2): 100–106
Bungum T, Satterwhite M, Jackson AW, et al. The relationship of body mass index, medical costs, and job absenteeism. Am J Health Behav 2003; 27 (4): 456–462
Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183: 514–519
Schwenkglenks M, Lowy A, Anderhub H, et al. Costs of asthma in a cohort of Swiss adults: associations with exacerbation status and severity. Value Health 2003; 6 (1): 75–83
Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the top 10 “physical and mental ” health conditions affecting six large US employers in 1999. J Occup Environ Med 2003; 45 (1): 5–14
Bonastre J, Le Pen C, Soubrane G, et al. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21 (3): 181–190
Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003; 21 (1): 116–122
Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003; 49 (1): 64–70
Perencevich EN, Sands KE, Cosgrove SE, et al. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003; 9 (2): 196–203
Roberts JA, Cumberland P, Sockett PN, et al. The study of infectious intestinal disease in England: socioeconomic impact. Epidemiol Infect 2003; 130 (1): 1–11
Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003; 97 (6): 1541–1550
Barcelo A, Aedo C, Rajpathak S, et al. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003; 81 (1): 19–27
Corso PS, Kramer MH, Blair KA, et al. Cost of illness in the 1993 waterborne Cryptosporidium outbreak, Milwaukee, Wisconsin. Emerg Infect Dis 2003; 9 (4): 426–431
Dockerty JD, Skegg DC, Williams SM. Economic effects of childhood cancer on families. J Paediatr Child Health 2003; 39 (4): 254–258
Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36 (11): 1397–1403
Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003; 26 (6): 1790–1795
Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31 (5): 1312–1317
Chesson HW, Pinkerton SD, Voigt R, et al. HIV infections and associated costs attributable to syphilis coinfection among African Americans. Am J Public Health 2003; 93 (6): 943–948
Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111 (6): 1212–1218
Daviglus ML, Liu K, Yan LL, et al. Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age. JAMA 2004; 292 (22): 2743–2749
Wolstenholme J, Fenn P, Gray A, et al. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002; 181: 36–42
Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 2002; 20 (2): 260–267
Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001; 119 (2): 344–352
Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch Fam Med 2000; 9 (10): 989–996
Druss BG, Rosenheck RA, Sledge WH. Health and disability costs of depressive illness in a major US corporation. Am J Psychiatry 2000; 157 (8): 1274–1278
Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000; 118 (5): 1278–1285
Cavigelli A, Fischer R, Dietz V. Socioeconomic outcome of paraplegia compared to lower limb amputation. Spinal Cord 2002; 40 (4): 174–177
Hedelin H, Holmang S, Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 2002; 36 (5): 344–347
O’Shea E, O’Reilly S. The economic and social cost of dementia in Ireland. Int J Geriatr Psychiatry 2000; 15 (3): 208–218
Max W, Rice DP, Sung HY, et al. The economic burden of prostate cancer, California, 1998. Cancer 2002; 94 (11): 2906–2913
Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46 (6): 850–860
Patel A, Knapp M, Henderson J, et al. The economic consequences of social phobia. J Affect Disord 2002; 68 (2–3): 221–233
Liu JW, Su YK, Liu CF, et al. Nosocomial blood-stream infection in patients with end-stage renal disease: excess length of hospital stay, extra cost and attributable mortality. J Hosp Infect 2002; 50 (3): 224–227
Wolf A, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6 (2): 97–106
Rein DB, Kassler WJ, Irwin KL, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95 (3): 397–402
Tarricone R, Gerzeli S, Montanelli R, et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study: Interdisciplinary Study Group on the Economic Impact of Schizophrenia. Health Policy 2000; 51 (1): 1–18
Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985–1994. J Allergy Clin Immunol 2000; 106 (3): 493–499
Taylor MC, Greig PD, Detsky AS, et al. Factors associated with the high cost of liver transplantation in adults. Can J Surg 2002; 45 (6): 425–434
Khetsuriani N, Holman RC, Anderson LJ. Burden of encephalitis-associated hospitalizations in the United States, 1988–1997. Clin Infect Dis 2002; 35 (2): 175–182
Scuvee-Moreau J, Kurz X, Dresse A, et al. The economic impact of dementia in Belgium: results of the National Dementia Economic Study (NADES). Acta Neurol Belg 2002; 102 (3): 104–113
Berto P, Degli Esposti E, Ruffo P, et al. The pandora project: cost of hypertension from a general practitioner database. Blood Press 2002; 11 (3): 151–156
Amonkar MM, Kalsekar ID, Boyer JG. The economic burden of Barrett’s esophagus in a Medicaid population. Ann Pharmacother 2002; 36 (4): 605–611
Babu BV, Nayak AN, Dhal K, et al. The economic loss due to treatment costs and work loss to individuals with chronic lymphatic filariasis in rural communities of Orissa, India. Acta Trop 2002; 82 (1): 31–38
March L, Cross M, Tribe K, et al. Cost of joint replacement surgery for osteoarthritis: the patients’ perspective. J Rheumatol 2002; 29 (5): 1006–1014
Dietrich ES, Demmler M, Schulgen G, et al. Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002; 30 (2): 61–67
Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden [published erratum appears in Pharmacoeconomics 2003; 21 (2): 148]. Pharmacoeconomics 2002; 20 (5): 347–355
Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249 (2): 152–163
Liu JL, Maniadakis N, Gray A, et al. The economic burden of coronary heart disease in the UK. Heart 2002; 88 (6): 597–603
Garfield FB, Getsios D, Caro JJ, et al. Assessment of Health Economics in Alzheimer’s Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002; 20 (9): 629–637
Max W, Sinnot P, Kao C, et al. The burden of osteoporosis in California, 1998. Osteoporos Int 2002; 13 (6): 493–500
Cooper NJ, Mugford M, Symmons DP, et al. Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatology 2002; 41 (7): 767–774
Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002; 59 (11): 1721–1729
Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002; 42 (6): 501–509
Li J, McCombs JS, Stimmel GL. Cost of treating bipolar disorder in the California Medicaid (MediCal) program. J Affect Disord 2002; 71 (1-3): 131–139
McGarry LJ, Thompson D, Millham FH, et al. Outcomes and costs of acute treatment of traumatic brain injury. J Trauma 2002; 53 (6): 1152–1159
Andersson A, Levin LA, Oberg B, et al. Health care and social welfare costs in home-based and hospital-based rehabilitation after stroke. Scand J Caring Sci 2002; 16 (4): 386–392
Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med 1999; 159 (18): 2177–2183
Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999; 22 Suppl. 2: S386–S393
Blomqvist P, Lycke J, Strang P, et al. Brain tumours in Sweden 1996: care and costs. J Neurol Neurosurg Psychiatry 2000; 69 (6): 792–798
Hirshberg J, Rees RS, Marchant B, et al. Osteomyelitis related to pressure ulcers: the cost of neglect. Adv Skin Wound Care 2000; 13 (1): 25–29
Baldwin ZK, Meyerson SL, Skelly CL, et al. Estimating the contemporary in-hospital costs of carotid endarterectomy. Ann Vasc Surg 2000; 14 (3): 210–215
Newhall-Perry K, Law NJ, Ramos B, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis: Western Consortium of Practicing Rheumatologists. J Rheumatol 2000; 27 (5): 1156–1163
Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41 (3): 342–351
Yang MC, Huang IC. Establishing a cost estimation model for hypertension and its related diseases in Taiwan. J Formos Med Assoc 1999; 98 (6): 394–402
Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17 (2): 197–208
Ehrnborg C, Hakkaart-Van Roijen L, Jonsson B, et al. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics 2000; 17 (6): 621–628
Tan HL. Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members. Pharmacoeconomics 2000; 17 (1): 77–107
Mauskopf JA, David K, Grainger DL, et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry 1999; 60 Suppl. 19: 14–19
Anis AH, Guh D, Stieb D, et al. The costs of cardiorespiratory disease episodes in a study of emergency department use. Can J Public Health 2000; 91 (2): 103–106
Kernick DP, Reinhold DM, Netten A. What does it cost the patient to see the doctor? Br J Gen Pract 2000; 50 (454): 401–403
Polednak AP. Hospital charges for colorectal cancer patients first admitted through an emergency department. J Health Care Finance 2000; 27 (1): 44–49
Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90 (10): 1562–1569
Levy P, Levy E, Audran M, et al. The cost of osteoporosis in men: the French situation. Bone 2002; 30 (4): 631–636
Jacobs P, Blanchard JF, James RC, et al. Excess costs of diabetes in the Aboriginal population of Manitoba, Canada. Can J Public Health 2000; 91 (4): 298–301
Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35 (3): 229–231
Wildhagen MF, Verheij JB, Verzijl JG, et al. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1 [published erratum appears in Thorax 1997 Feb; 52 (2): 204. Note: Habbema F corrected to Habbema JD]. Thorax 1996; 51 (3): 298–301
Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology 1998; 51 (3): 355–361
Ramaiah KD, Ramu K, Guyatt H, et al. Direct and indirect costs of the acute form of lymphatic filariasis to households in rural areas of Tamil Nadu, south India. Trop Med Int Health 1998; 3 (2): 108–115
Rouillon F, Toumi M, Dansette GY, et al. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997; 11 (6): 578–594
Montron A, Guignard E, Pelc A, et al. Peripheral arterial obliterative disease: cost of illness in France. Pharmacoeconomics 1998; 13 (1 Pt 1): 51–59
Hakkaart-van Roijen L, Beckers A, Stevenaert A, et al. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 1998; 14 (4): 395–403
Reginster JY, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999; 15 (5): 507–514
Guest JF, Cookson RF. Cost of schizophrenia to UK Society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999; 15 (6): 597–610
LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson’s disease. Pharmacoeconomics 1999; 16 (1): 59–69
Plumb JM, Guest JF. Annual cost of erectile dysfunction to UK Society. Pharmacoeconomics 1999; 16 (6): 699–709
Lane A. Direct costs of osteoporosis for New Zealand women. Pharmacoeconomics 1996; 9 (3): 231–245
Petrou S, Dooley M, Whitaker L, et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. Pharmacoeconomics 1996; 9 (4): 332–340
Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States [published erratum appears in Clin Ther 1999 Feb; 21 (2): 430]. Clin Ther 1998; 20 (5): 993–1008
Devlin NJ, Scuffham PA, Bunt LJ. The social costs of alcohol abuse in New Zealand. Addiction 1997; 92 (11): 1491–1505
Muller C, Fahs MC, Mulak G, et al. Pediatric AIDS at Mount Sinai Medical Center 1988-89: a study of costs and social severity. Soc Work Health Care 1996; 22 (4): 1–20
Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159 (8): 813–818
Single E, Robson L, Xie X, et al. The economic costs of alcohol, tobacco and illicit drugs in Canada, 1992. Addiction 1998; 93 (7): 991–1006
Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997; 19 (6): 1470–1495
Ray NF, Denton WG, Thamer M, et al. Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994. J Am Coll Surg 1998; 186 (1): 1–9
Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998; 81 (9): 1110–1115
Metcalf M, Brown N, Peterson S, et al. Health care costs associated with chronic hepatitis B. Am J Health Syst Pharm 1999; 56 (3): 232–236
MacKinnon NJ, Flagstad MS, Peterson CR, et al. Disease management program for asthma: baseline assessment of resource use. Am J Health Syst Pharm 1996; 53 (5): 535–541
McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35 (8): 781–790
Mathias SD, Kuppermann M, Liberman RF, et al. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol 1996; 87 (3): 321–327
Sauerborn R, Nougtara A, Hien M, et al. Seasonal variations of household costs of illness in Burkina Faso. Soc Sci Med 1996; 43 (3): 281–290
Clarke AE, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24 (6): 1051–1060
Konradsen F, van der Hoek W, Amerasinghe PH, et al. Household responses to malaria and their costs: a study from rural Sri Lanka. Trans R Soc Trop Med Hyg 1997; 91 (2): 127–130
Buzby JC, Roberts T. Economic costs and trade impacts of microbial foodborne illness. World Health Stat Q 1997; 50 (12): 57–66
Asenso-Okyere WK, Dzator JA. Household cost of seeking malaria care: a retrospective study of two districts in Ghana. Soc Sci Med 1997; 45 (5): 659–667
Woo J, Ho SC, Chan SG, et al. An estimate of chronic disease burden and some economic consequences among the elderly Hong Kong population. J Epidemiol Community Health 1997; 51 (5): 486–489
Sagmeister M, Gessner U, Oggier W, et al. An economic analysis of ischaemic heart disease in Switzerland. Eur Heart J 1997; 18 (7): 1102–1109
Swinburn B, Ashton T, Gillespie J, et al. Health care costs of obesity in New Zealand. Int J Obes Relat Metab Disord 1997; 21 (10): 891–896
Callender TJ, Ristovv M, Guerra M, et al. Social and economic impact of neurotoxicity in hazardous waste workers in Lenoir, North Carolina. Environ Res 1997; 73 (1-2): 166–174
Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156 (3 Pt 1): 787–793
Buzby JC, Allos BM, Roberts T. The economic burden of Campylobacter-associated Guillain-Barre syndrome. J Infect Dis 1997; 176 Suppl. 2: S192–S197
Healey A, Knapp M, Astin J, et al. Economic burden of drug dependency: social costs incurred by drug users at intake to the National Treatment Outcome Research Study. Br J Psychiatry 1998; 173: 160–165
Clark KL, Howell RM, Scott RM, et al. The socioeconomic impact of hepatitis E in Nepal. Am J Trop Med Hyg 1999; 61 (3): 505–510
Evers SM, Engel GL, Ament AJ. Cost of stroke in The Netherlands from a societal perspective. Stroke 1997; 28 (7): 1375–1381
Warner DC, McCandless RR, De Nino LA, et al. Costs of diabetes in Texas, 1992. Diabetes Care 1996; 19 (12): 1416–1419
Chesson HW, Pinkerton SD, Irwin KL, et al. New HIV cases attributable to syphilis in the USA: estimates from a simplified transmission model. AIDS 1999; 13 (11): 1387–1396
Meerding WJ, Bonneux L, Polder JJ, et al. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ 1998; 317 (7151): 111–115
Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76 (2): 159–162
Goeree R, O’Brien BJ, Goering P, et al. The economic burden of schizophrenia in Canada. Can J Psychiatry 1999; 44 (5): 464–472
Chew FT, Goh DY, Lee BW. The economic cost of asthma in Singapore. Aust N Z J Med 1999; 29 (2): 228–233
Pichichero ME, Treanor J. Economic impact of pertussis. Arch Pediatr Adolesc Med 1997; 151 (1): 35–40
Kurz X, Broers M, Scuvee-Moreau J, et al. Methodological issues in a cost-of-dementia study in Belgium: the NAtional Dementia Economic Study (NADES). Acta Neurol Belg 1999; 99 (3): 167–175
Patience D, Buxton M, Chick J, et al. The SECCAT Survey: II. The Alcohol Related Problems Questionnaire as a proxy for resource costs and quality of life in alcoholism treatment. Study of Socio-Economic Consequences and Costs of Alcoholism and Treatment. Alcohol Alcohol 1997; 32 (1): 79–84
Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997; 45 (3): 281–287
De Graeve D, Lescrauwaet B, Nonneman W. Patient classification and cost analysis of AIDS and HIV: the case of Belgium [published erratum appears in Health Policy 1997 Jun; 40 (3): 265]. Health Policy 1997; 39 (2): 93–106
Zethraeus N, Molin T, Henriksson P, et al. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246 (2): 151–159
Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. J Intern Med 1998; 244 (6): 461–468
Kiiskinen U, Vartiainen E, Puska P, et al. Long-term cost and life-expectancy consequences of hypertension. J Hypertens 1998; 16 (8): 1103–1112
Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1 Pt 1): 22–27
Lozano P, Sullivan SD, Smith DH, et al. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol 1999; 104 (5): 957–963
Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev Med 1999; 29 (3): 173–186
Miller VL, Rice JC, DeVoe M, et al. An analysis of program and family costs of case managed care for technology-dependent infants with bronchopulmonary dysplasia. J Pediatr Nurs 1998; 13 (4): 244–251
Rutten-van Molken MP, Postma MJ, Joore MA, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999; 93 (11): 779–787
Fornaro P, Gandini F, Marin M, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Italian Sentinel Group on Pediatric Infectious Diseases. Pediatr Infect Dis J 1999; 18 (5): 414–419
Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT). Pediatrics 1999; 104 (1 Pt 1): 7–14
Bowie RD, Tobias MI, Williams T. The private costs of HIV/AIDS. N Z Med J 1996; 109 (1016): 51–54
Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol 1996; 49 (1): 95–103
Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 2000; 19 (2): 87–99
Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 1997; 349 (9052): 604–608
Zmirou D, Deloraine A, Balducci F, et al. Health effects costs of particulate air pollution. J Occup Environ Med 1999; 41 (10): 847–856
Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J 1999; 13 (2): 281–286
Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12 (6): 1322–1326
Kiiskinen U, Vartiainen E, Pekurinen M, et al. Does prevention of cardiovascular diseases lead to decreased cost of illness? Twenty years of experience from Finland. Prev Med 1997; 26 (2): 220–226
Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001; 98 (3): 398–406
Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 401–407
Ray NF, Baraniuk JN, Thamer M, et al. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 408–414
Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27 (4): 781–788
Torgerson PR, Dowling PM. Estimating the economic effects of cystic echinococcosis. Part 2: an endemic region in the United Kingdom, a wealthy, industrialized economy. Ann Trop Med Parasitol 2001; 95 (2): 177–185
Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002; 46 (1): 223–231
Ungar WJ, Coyte PC, Pharmacy Medication Monitoring Program Advisory B. Prospective study of the patient-level cost of asthma care in children. Pediatr Pulmonol 2001; 32 (2): 101–108
Yelin E, Herrndorf A, Trupin L, et al. A national study of medical care expenditures for musculoskeletal conditions: the impact of health insurance and managed care. Arthritis Rheum 2001; 44 (5): 1160–1169
Santos R, Cifaldi M, Gregory C, et al. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Manag Care 1999; 5 (4 Suppl.): S225–S234
Tollestrup K, Frost FJ, Stidley CA, et al. The excess costs of breast cancer health care in Hispanic and non-Hispanic female members of a managed care organization. Breast Cancer Res Treat 2001; 66 (1): 25–31
Lapins DL, Urdaneta ME, Barrett J, et al. Costs of care for HIV infection in a managed care population from 1995 to 1997. Am J Manag Care 2000; 6 (9): 973–981
Soni A, Sonnenberg A. Healthcare resource utilization in the management of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2001; 15 (7): 945–951
van Jaarsveld CH, Jacobs JW, Schrijvers AJ, et al. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998; 37 (8): 837–847
Sutcliffe N, Clarke AE, Taylor R, et al. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology 2001; 40 (1): 37–47
Mark TL, Woody GE, Juday T, et al. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61 (2): 195–206
Zimmerman CM, Bresee JS, Parashar UD, et al. Cost of diarrhea-associated hospitalizations and outpatient visits in an insured population of young children in the United States. Pediatr Infect Dis J 2001; 20 (1): 14–19
Lyu RR, McCombs JS, Johnstone BM, et al. Use of conventional antipsychotics and the cost of treating schizophrenia. Health Care Financ Rev 2001; 23 (2): 83–99
McNamee P, Bond J, Buck D, et al. Costs of dementia in England and Wales in the 21st century. Br J Psychiatry 2001; 179: 261–266
Chan AT, Jacobs P, Yeo W, et al. The cost of palliative care for hepatocellular carcinoma in Hong Kong. Pharmacoeconomics 2001; 19 (9): 947–953
Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96 (11): 3122–3129
van Agthoven M, van Ineveld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001; 37 (17): 2204–2211
Szucs TD, Berger K, Fisman DN, et al. The estimated economic burden of genital herpes in the United States: an analysis using two costing approaches. BMC Infect Dis 2001; 1: 5
Thomas SV, Sarma PS, Alexander M, et al. Economic burden of epilepsy in India. Epilepsia 2001; 42 (8): 1052–1060
Decock RC, Depoorter AM, De Graeve D, et al. Direct costs of health care for HIV/AIDS patients in Belgium. AIDS Care 2001; 13 (6): 721–731
Birnbaum HG, Morley M, Greenberg PE, et al. Economic burden of pneumonia in an employed population. Arch Intern Med 2001; 161 (22): 2725–2731
Morgan CL, Kerr MP. Estimated cost of inpatient admissions and outpatient appointments for a population with epilepsy: a record linkage study. Epilepsia 2004; 45 (7): 849–854
Dranitsaris G, Maroun J, Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer 2005; 13 (5): 318–324
Hakkaart-van Roijen L, Hoeijenbos MB, Regeer EJ, et al. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand 2004; 110 (5): 383–392
Bownds L, Lindekugel R, Stepak P. Economic impact of a hepatitis A epidemic in a midsized urban community: the case of Spokane, Washington. J Community Health 2003; 28 (4): 233–246
Khetsuriani N, Quiroz ES, Holman RC, et al. Viral meningitis-associated hospitalizations in the United States, 1988–1999. Neuroepidemiology 2003; 22 (6): 345–352
Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S43–S50
Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S61–S69
Beghi E, Garattini L, Ricci E, et al. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004; 45 (2): 171–178
Utz JT, Apperson CS, MacCormack JN, et al. Economic and social impacts of La Crosse encephalitis in western North Carolina. Am J Trop Med Hyg 2003; 69 (5): 509–518
Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (7): 2358–2363
Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff (Millwood) 2003; Suppl Web Exclusives: W3-219-26
de Zelicourt M, Dardennes R, Verdoux H, et al. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. Pharmacoeconomics 2003; 21 (15): 1081–1090
Lodha R, Puranik M, Kattal N, et al. Social and economic impact of childhood asthma. Indian Pediatr 2003; 40 (9): 874–879
Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6 (1): 59–74
Weinmann S, Kamtsiuris P, Henke KD, et al. The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr Allergy Immunol 2003; 14 (1): 18–26
McCrone P, Darbishire L, Ridsdale L, et al. The economic cost of chronic fatigue and chronic fatigue syndrome in UK primary care. Psychol Med 2003; 33 (2): 253–261
Le Pen C, Ruszniewski P, Gaudin AF, et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol 2004; 39 (4): 336–343
Johnson RL, Brooks CA, Whiteneck GG. Cost of traumatic spinal cord injury in a population-based registry. Spinal Cord 1996; 34 (8): 470–480
Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry Suppl 1998; (34): 4–9
Guo JJ, Gibson JT, Gropper DM, et al. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus. Am J Manag Care 1998; 4 (10): 1433–1446
Garattini L, Tediosi F, Chiaffarino F, et al. The outpatient cost of diabetes care in Italian diabetes centers. Value Health 2001; 4 (3): 251–257
White AG, Birnbaum HG, Mareva MN, et al. Economic burden of illness for employees with painful conditions. J Occup Environ Med 2005; 47 (9): 884–892
Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147 (1): 121–126
Centers for Disease Control and Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment: United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53 (3): 57–59
Schmid A, Burchard H, Clouth J, et al. Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ 2002; 3: 377–382
Dodel R, Peter H, Walbert T, et al. The socioeconomic impact of narcolepsy. Sleep 2004; 27 (6): 1123–1128
Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005; 21 (2): 195–206
Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48 (7): 515–524
Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004; 11 (1): 17–33
Maumbe BM, Swinton SM. Hidden health costs of pesticide use in Zimbabwe’s smallholder cotton growers. Soc Sci Med 2003; 57 (9): 1559–1571
Fendrick AM, Monto AS, Nightengale B, et al. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 2003; 163 (4): 487–494
Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163 (8): 929–935
Stevens CA, Turner D, Kuehni CE, et al. The economic impact of preschool asthma and wheeze. Eur Respir J 2003; 21 (6): 1000–1006
Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002; 180: 227–233
Polder JJ, Meerding WJ, Bonneux L, et al. Healthcare costs of intellectual disability in the Netherlands: a cost-of-illness perspective. J Intell Disabil Res 2002; 46 (Pt 2): 168–178
Beutels P, Van Damme P, Van Casteren V, et al. The difficult quest for data on ‘vanishing’ vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 2002; 20 (29-30): 3551–3559
Stenevi U, Lundstrom M, Thorburn W. The cost of cataract patients awaiting surgery. Acta Ophthalmol Scand 2000; 78 (6): 703–705
Attanayake N, Fox-Rushby J, Mills A. Household costs of ‘malaria’ morbidity: a study in Matale district, Sri Lanka. Trop Med Int Health 2000; 5 (9): 595–606
Detournay B, Fagnani F, Phillippo M, et al. Obesity morbidity and health care costs in France: an analysis of the 1991–1992 Medical Care Household Survey. Int J Obes Relat Metab Disord 2000; 24 (2): 151–155
Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol 1996; 135 (1): 20–23
Simmons D, Peng A, Cecil A, et al. The personal costs of diabetes: a significant barrier to care in South Auckland. N Z Med J 1999; 112 (1097): 383–385
Withington SG, Chambers ST. The cost of campylobacteriosis in New Zealand in 1995. N Z Med J 1997; 110 (1046): 222–224
Suleiman TG, Ohaeri JU, Lawal RA, et al. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry 1997; 171: 364–368
Wimo A, Karlsson G, Sandman PO, et al. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997; 12 (8): 857–861
Dowell CJ, Bryant CM, Moore KH, et al. Calculating the direct costs of urinary incontinence: a new test instrument. BJU Int 1999; 83 (6): 596–606
Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: part I. Cost of uncomplicated cases. Pediatrics 1999; 104 (1 Pt 1): 1–6
Carabin H, Gyorkos TW, Soto JC, et al. Estimation of direct and indirect costs because of common infections in toddlers attending day care centers. Pediatrics 1999; 103 (3): 556–564
Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004; 63 (3): 461–465
Nguyen PM, Kenny DJ, Barrett EJ. Socio-economic burden of permanent incisor replantation on children and parents. Dent Traumatol 2004; 20 (3): 123–133
Wang G, Helmick CG, Macera C, et al. Inactivity-associated medical costs among US adults with arthritis. Arthritis Rheumat 2001; 45 (5): 439–445
Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001; 144 (3): 514–522
Janssen I, Shepard DS, Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 2004; 52 (1): 80–85
Babu BV, Nayak AN. Treatment costs and work time loss due to episodic adenolymphangitis in lymphatic filariasis patients in rural communities of Orissa, India. Trop Med Int Health 2003; 8 (12): 1102–1109
Alberini A, Krupnick A. Cost-of-illness and willingness-to-pay estimates of the benefits of improved air quality: evidence from Taiwan. Land Econ 2000; 76 (1): 37–53
Hamelsky SW, Lipton RB, Stewart WF. An assessment of the burden of migraine using the willingness to pay model. Cephalalgia 2005; 25 (2): 87–100
Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005; 173 (4): 1309–1313
Chesson HW, Blandford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004; 36 (1): 11–19
Lapsley HM, March LM, Tribe KL, et al. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 2002; 61 (9): 818–821
Rendu A, Moran P, Patel A, et al. Economic impact of personality disorders in UK primary care attenders. Br J Psychiatry 2002; 181: 62–66
Rockwood K. Vascular cognitive impairment and vascular dementia. J Neurol Sci 2002; 203-204: 23–27
Hussey LC, Hardin S, Blanchette C. Outpatient costs of medications for patients with chronic heart failure. Am J Crit Care 2002; 11 (5): 474–478
Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162 (18): 2061–2069
Severens JL, Habraken JM, Duivenvoorden S, et al. The cost of illness of pressure ulcers in The Netherlands. Adv Skin Wound Care 2002; 15 (2): 72–77
Fillit H, Hill J. The costs of vascular dementia: a comparison with Alzheimer’s disease. J Neurol Sci 2002; 203-204: 35–39
Birnbaum HG, Berger WE, Greenberg PE, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol 2002; 109 (2): 264–270
Krappweis J, Rentsch A, Schwarz UI, et al. Outpatient costs of osteoporosis in a national health insurance population. Clin Ther 1999; 21 (11): 2001–2014
Feldman SR, Fleischer Jr AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37 (4): 564–569
Hux MJ, O’Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer’s disease and costs of caring. CMAJ 1998; 159 (5): 457–465
Patricoski CT, Steiner G. Cost of medications for patients with ischemic heart disease in a rural family practice center. J Am Board Fam Pract 1999; 12 (3): 200–205
Petruzzelli GJ, Brockenbrough JM, Vandevender D, et al. The influence of reconstructive modality on cost of care in head and neck oncologic surgery. Arch Otolaryngol Head Neck Surg 2002; 128 (12): 1377–1380
Dewey HM, Thrift AG, Mihalopoulos C, et al. Informal care for stroke survivors: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2002; 33 (4): 1028–1033
Kirchner V, Elloy MD, Silver LE, et al. Dementia: the cost of care for behaviourally disturbed patients living in the community. Int J Geriatr Psychiatry 2000; 15 (11): 1000–1004
Sundberg G, Bagust A, Terent A. A model for costs of stroke services. Health Policy 2003; 63 (1): 81–94
Shih YC, Hartzema AG, Tolleson-Rinehart S. Labor costs associated with incontinence in long-term care facilities. Urology 2003; 62 (3): 442–446
Bernal P, Estroff DB, Aboudarham JF, et al. Psychosocial morbidity: the economic burden in a pediatric health maintenance organization sample. Arch Pediatr Adolesc Med 2000; 154 (3): 261–266
Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003; 98 (5): 1064–1072
Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 2003; 98 (4): 844–849
Merkesdal S, Ruof J, Huelsemann JL, et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005; 53 (2): 234–240
Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. J Occup Environ Med 2005; 47 (5): 439–446
Vijan S, Hayward RA, Langa KM. The impact of diabetes on workforce participation: results from a national household sample. Health Serv Res 2004; 39 (6 Pt 1): 1653–1669
Rosen S, Vincent JR, MacLeod W, et al. The cost of HIV/AIDS to businesses in southern Africa. AIDS 2004; 18 (2): 317–324
Oliva J, Roa C, del Llano J. Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study. Pharmacoeconomics 2003; 21 (15): 1113–11121
Frick KD, Basilion EV, Hanson CL, et al. Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol 2003; 10 (2): 121–132
Frick KD, Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 2003; 135 (4): 471–476
Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003; 290 (18): 2443–2454
Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression [published erratum appears in JAMA 2003 Oct 22; 290 (16): 2218]. JAMA 2003; 289 (23): 3135–3144
Boden LI, Galizzi M. Economic consequences of workplace injuries and illnesses: lost earnings and benefit adequacy. Am J Ind Med 1999; 36 (5): 487–503
Onwujekwe O, Chima R, Okonkwo P. Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holoendemic Nigerian communities. Health Policy 2000; 54 (2): 143–159
Boonen A, van der Heijde D, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61 (5): 429–437
Ward MM, Javitz HS, Smith WM, et al. Lost income and work limitations in persons with chronic respiratory disorders. J Clin Epidemiol 2002; 55 (3): 260–268
de Loes M, Jansson B. Work-related acute injuries from mandatory fitness training in the Swedish Police Force. Int J Sports Med 2002; 23 (3): 212–217
Bramley TJ, Lerner D, Sames M. Productivity losses related to the common cold. J Occup Environ Med 2002; 44 (9): 822–829
Yassin AS, Beckles GL, Messonnier ML. Disability and its economic impact among adults with diabetes. J Occup Environ Med 2002; 44 (2): 136–142
Pop PH, Gierveld CM, Karis HA, et al. Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. Eur J Neurol 2002; 9 (2): 171–174
Myles S, Douglas MJ, Ward HJ, et al. Variant Creutzfeldt-Jakob disease: costs borne by families. Health Soc Care Community 2002; 10 (2): 91–98
Valdmanis V, Smith DW, Page MR. Productivity and economic burden associated with diabetes. Am J Public Health 2001; 91 (1): 129–130
Ruben RJ. Redefining the survival of the fittest: communication disorders in the 21st century. Laryngoscope 2000; 110 (2 Pt 1): 241–245
Herrin J, Cangialose CB, Boccuzzi SJ, et al. Household income losses associated with ischaemic heart disease for US employees. Pharmacoeconomics 2000; 17 (3): 305–314
Konradsen F, van der Hoek W, Amerasinghe PH, et al. Measuring the economic cost of malaria to households in Sri Lanka. Am J Trop Med Hyg 1997; 56 (6): 656–660
Anand K, Pandav CS, Nath LM. Impact of HIV/AIDS on the national economy of India. Health Policy 1999; 47 (3): 195–205
Hutubessy RC, van Tulder MW, Vondeling H, et al. Indirect costs of back pain in the Netherlands: a comparison of the human capital method with the friction cost method. Pain 1999; 80 (1-2): 201–207
Guico-Pabia CJ, Murray JF, Teutsch SM, et al. Indirect cost of ischemic heart disease to employers. Am J Manag Care 2001; 7 (1): 27–34
Crystal-Peters J, Crown WH, Goetzel RZ, et al. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000; 6 (3): 373–378
Mullins CD, Whitelaw G, Cooke JL, et al. Indirect cost of HIV infection in England. Clin Ther 2000; 22 (11): 1333–1345
Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16 (11): 770–778
Grassly NC, Desai K, Pegurri E, et al. The economic impact of HIV/AIDS on the education sector in Zambia. AIDS 2003; 17 (7): 1039–1044
Acknowledgements
Dr Akobundu acknowledges the financial support of the Pharmaceutical Research and Manufacturers of America Foundation through its Post-Doctoral Fellowship in Health Outcomes. The authors have no relevant conflicts of interest to declare. All the authors made substantial contributions to the intellectual content of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akobundu, E., Ju, J., Blatt, L. et al. Cost-of-Illness Studies. Pharmacoeconomics 24, 869–890 (2006). https://doi.org/10.2165/00019053-200624090-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200624090-00005